How should an adult male with penile shrinkage be evaluated and treated?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Evaluation and Treatment of Penile Shrinkage in Adult Males

Men presenting with penile shrinkage require immediate assessment to distinguish between true pathological shortening (post-surgical, Peyronie's disease, hormonal deficiency) versus normal anatomical variation with body dysmorphic concerns—treatment depends entirely on identifying the underlying cause through targeted history, testosterone measurement, and physical examination with stretched penile length measurement.

Initial Diagnostic Approach

Key Historical Elements to Obtain

  • Temporal pattern: Sudden vs. gradual onset, duration of symptoms
  • Surgical history: Prior prostatectomy, pelvic radiation, or androgen suppression therapy 1
  • Penile deformity: Presence of curvature, palpable plaques, or pain suggesting Peyronie's disease 2
  • Erectile function: Morning/nocturnal erections, ability to achieve penetration-grade rigidity 3
  • Hormonal symptoms: Decreased libido, fatigue, mood changes indicating possible testosterone deficiency 3
  • Baseline penile dimensions: Patient's recollection of pre-morbid size

Physical Examination Specifics

Measure stretched penile length from pubic bone (with prepubic fat depressed) to glans tip under maximum manual traction 4. This is the standard anthropometric measure.

Examine the penis in stretched position, palpating from pubic bone to coronal sulcus for plaques or deformities 3. Note that absence of palpable plaque does not exclude Peyronie's disease.

Mandatory Laboratory Testing

Morning serum total testosterone must be measured in all men with penile concerns 3. Testosterone deficiency is defined as total testosterone <300 ng/dL with accompanying symptoms 3.

Treatment Based on Etiology

Post-Surgical Penile Shortening

Following radical prostatectomy, expect approximately 1 cm of shortening up to 12-24 months, with potential recovery beginning at 24 months and complete re-establishment by 48 months 4. Preserved erectile function predicts earlier penile length recovery 4.

Penile rehabilitation interventions:

  • Vacuum erection devices (VED): Most evidence-supported intervention. VED prevents corporeal veno-occlusive dysfunction and preserves tunica albuginea, endothelial, and smooth muscle cell structure 5. Use regularly as part of rehabilitation protocol.

  • Daily PDE5 inhibitors: Enhance nocturnal erections and tissue perfusion 6. Prescribe tadalafil, sildenafil, vardenafil, or avanafil with proper dosing instructions 3.

  • Penile traction therapy: Can increase flaccid length by <2 cm in post-surgical patients 7, 8

Critical caveat: Patients undergoing androgen suppression plus radiation therapy experience significant penile shortening (mean 14.2 to 8.6 cm) and should be counseled preoperatively that this may occur 1.

Peyronie's Disease with Shortening

Distinguish between active disease (dynamic symptoms, penile pain, progressive deformity) and stable disease (unchanged ≥3 months, minimal/no pain) 2.

For stable disease with severe shortening, curvature >60°, or complex deformities without erectile dysfunction:

  • Tunical lengthening procedures with graft coverage (autografts, allografts, or xenografts) 6
  • Postoperative penile rehabilitation with VED and daily PDE5 inhibitors 6
  • Warning: Up to 50% risk of postoperative erectile dysfunction 6

For Peyronie's disease with concurrent erectile dysfunction:

  • Penile prosthesis implantation is indicated when ED is unresponsive to medical therapy 6
  • Mild-to-moderate curvature often resolves with cylinder insertion alone 6
  • Patient satisfaction rates are lower than general ED cases due to length concerns 6

Testosterone Deficiency

For confirmed hypogonadism (testosterone <300 ng/dL with symptoms):

Mandatory pre-treatment screening 9:

  • Digital rectal examination
  • Prostate-specific antigen level
  • Hematocrit
  • Refer to urology if prostate abnormalities detected

Testosterone replacement options 9:

  • Intramuscular: 50-150 mg testosterone enanthate/cypionate every 7-14 days (preferred over traditional 200-300 mg every 2-3 weeks)
  • Transdermal patches: Nonscrotal patches applied daily, maintain stable mid-normal range levels
  • 1% testosterone gel: Dose-dependent levels with less variability than patches

Follow-up schedule: Reassess at 1-3 months, then every 6-12 months monitoring for prostate issues, sleep apnea, edema, and erythrocytosis (hematocrit >52%) 9.

Normal Penile Size with Body Dysmorphic Concerns

When stretched penile length measurements are objectively normal:

First-line intervention is structured counseling 10, 7. The majority of men come to understand their penis is normal and become unwilling to pursue further treatment after proper education 7.

If patient still seeks enhancement after counseling:

  • Penile extenders/traction devices: Only non-surgical option with evidence for increasing flaccid length, though gains are <2 cm 7, 8

Avoid or strongly discourage:

  • Injectable fillers: High complication rates despite girth increase 7
  • Surgical interventions: Scant, low-quality evidence; frequent complications; should remain unethical outside clinical trials 7
  • Vacuum devices for enlargement: Do not increase size 7

Critical Pitfalls to Avoid

  1. Do not pursue penile augmentation surgery in men with normal anatomy outside of research protocols with ethics committee oversight 10

  2. Do not skip testosterone measurement—this is a moderate recommendation with Grade C evidence for all men presenting with sexual concerns 3

  3. Do not operate on Peyronie's disease during active phase—wait for stable disease (≥3 months unchanged) 2

  4. Do not ignore cardiovascular risk—erectile dysfunction is as strong a predictor of cardiac events as smoking or family history of MI 3. Communicate this to patient and primary care provider.

  5. Do not dismiss psychological factors—consider referral to mental health professional to reduce performance anxiety and integrate treatments 3

References

Guideline

peyronie's disease: aua guideline.

The Journal of urology, 2015

Guideline

erectile dysfunction: aua guideline.

The Journal of urology, 2018

Guideline

american association of clinical endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple's problem--2003 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.